

## Japan's Daiichi Sankyo unveils new Toronto headquarters to accelerate investment and innovation in oncology

23 January 2026 | News

### Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines



Japan-based pharmaceutical firm Daiichi Sankyo has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.

"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care."

Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.

To mark the occasion, Daiichi Sankyo hosted an office opening celebration featuring a traditional *Kagami Biraki* (sake barrel breaking) ceremony, symbolizing new beginnings, harmony and prosperity, followed by a Japanese *taiko* drumming performance honouring the company's cultural heritage. The event brought together company leadership, government representatives and partners to commemorate the milestone.

The official opening of the Daiichi Sankyo headquarters in Canada cements its position as a dedicated partner in the Canadian healthcare system. Driven by strategic investment and a rapidly expanding team, Daiichi Sankyo is focused on accelerating access to its oncology pipeline and building a healthier future for Canadians.